Management of Disseminated Intravascular Coagulation (DIC)

Core Management Algorithm

The International Society on Thrombosis and Haemostasis (ISTH) recommends treating the underlying disease process as the cornerstone of therapy for DIC, addressing the root cause of the coagulopathy 1, 2
In cancer-associated DIC, the ISTH guidelines suggest initiating appropriate cancer therapy immediately, such as chemotherapy, surgery, or radiation as indicated 1, 2
For acute promyelocytic leukemia, early initiation of all-trans retinoic acid achieves good resolution of DIC, as recommended by the ISTH 3
In sepsis-associated DIC, source control and appropriate antibiotics are essential, according to the ISTH guidelines 4

The ISTH classifies DIC into three distinct forms: procoagulant DIC (thrombosis predominates), hyperfibrinolytic DIC (bleeding predominates), and subclinical DIC, each requiring different management approaches 5, 6
Procoagulant DIC is common in pancreatic cancer and adenocarcinomas, presenting with arterial ischemia, venous thromboembolism, or microvascular thrombosis, as described by the ISTH 5, 7, 6
Hyperfibrinolytic DIC is typical of acute promyelocytic leukemia and metastatic prostate cancer, presenting with widespread bleeding from multiple sites, according to the ISTH 5, 7, 6

The ISTH recommends maintaining a platelet count >50×10⁹/L through platelet transfusions for active bleeding 3, 4, 8
For prolonged coagulation times, the ISTH suggests administering 15-30 mL/kg of fresh frozen plasma (FFP) 3, 4, 8
The ISTH recommends replacing fibrinogen with cryoprecipitate or fibrinogen concentrate if levels remain <1.5 g/L despite FFP 3, 4, 8

The ISTH recommends initiating prophylactic anticoagulation with heparin in all patients except those with hyperfibrinolytic DIC, unless contraindications exist 1, 2, 9, 3
The ISTH suggests using low molecular weight heparin (LMWH) as the first choice for most patients 3
The ISTH recommends escalating to therapeutic-dose anticoagulation if arterial or venous thrombosis develops 1, 2, 9

The ISTH recommends monitoring complete blood count and coagulation screen (including fibrinogen and D-dimer) regularly, with frequency ranging from daily in acute severe DIC to monthly in chronic stable DIC 10, 7, 3
A 30% or greater drop in platelet count is diagnostic of subclinical DIC, even when absolute values remain normal, according to the ISTH 10, 7, 8
The ISTH suggests considering temporary IVC filter placement in patients who cannot be anticoagulated but have proximal lower limb thrombosis likely to embolize 1, 2

The International Society on Thrombosis and Haemostasis (ISTH) recommends using a two-step sequential screening approach to identify patients who will benefit from specific therapies, first screening for Sepsis-Induced Coagulopathy (SIC) using the ISTH SIC score (≥4 points indicates SIC), and then applying the ISTH overt DIC score (≥5 points indicates overt DIC) for patients with more advanced coagulopathy 11, 12
The ISTH scoring components include platelet count, PT ratio, fibrinogen, D-dimer/FDP, and SOFA score (for SIC) 11, 12
Sequential screening on ICU admission day and 2 days later is associated with lower mortality 11

Anticoagulant therapy may improve outcomes specifically in septic patients with coagulopathy or DIC, though evidence remains controversial 11, 12
The ISTH suggests that patients with advanced overt DIC may have illness progression no longer amenable to anticoagulant therapy benefit 11